Anti-Colorectal Cancer Effect via Application of Polyethylene Glycol Modified Liposomal Apatinib

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• Metastatic colorectal cancer presents significant management challenges with limited effective treatments.
• Tumor angiogenesis, crucial for growth and metastasis, is a key therapeutic target.
• Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors have shown promise in cancer therapy.

Purpose of the Study:

• To synthesize and evaluate PEG-modified liposomal Apatinib (Apatinib-Lipo/PEG) for colorectal cancer treatment.
• To investigate the anti-tumor efficacy and mechanisms of Apatinib-Lipo/PEG in preclinical colorectal cancer models.
• To assess the safety and toxicity profile of Apatinib-Lipo/PEG.

Main Methods:

• Synthesis of PEG-modified liposomal Apatinib (Apatinib-Lipo/PEG).
• In vitro assessment of Apatinib-Lipo/PEG on CT26 cell proliferation and apoptosis.
• In vivo evaluation of Apatinib-Lipo/PEG in subcutaneous and peritoneal colorectal cancer models.
• Analysis of anti-tumor mechanisms including proliferation, apoptosis, and angiogenesis inhibition.

Main Results:

• Apatinib-Lipo/PEG demonstrated significant inhibition of CT26 cell proliferation and induction of apoptosis in vitro.
• Apatinib-Lipo/PEG markedly reduced tumor growth in both subcutaneous and peritoneal colorectal cancer models.
• The treatment exhibited minimal observable toxicity in the tested models.
• Key anti-tumor mechanisms identified were inhibition of proliferation, promotion of apoptosis, and suppression of tumor angiogenesis.

Conclusions:

• Apatinib-Lipo/PEG is a promising therapeutic agent for colorectal cancer treatment.
• The enhanced drug delivery system overcomes Apatinib's poor water solubility, improving efficacy.
• Apatinib-Lipo/PEG offers a potentially effective and safe strategy for managing metastatic colorectal cancer by targeting angiogenesis.